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Aims: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart-muscle 
disease primarily affecting the right ventricle and potentially causing sudden death in young people. 
Our aims are to analyse the progression over time of electrocardiographic(ECG) findings and to 
investigate their prognostic impact.   
Methods: 68 patients (69% men; age 31±19 years) with ARVC diagnosis were followed-up for a 
mean of 17±8 years. Follow-up included baseline ECG, 24-hour Holter ECG, signal-averaged ECG, 
stress test, echocardiography, cardiac magnetic resonance and electrophysiologic study (ES).  
Results: During follow-up 12 (18%) patients died: 3 for sudden cardiac death (SCD), 4 for end-
stage heart failure (HF), and 5 for non-cardiac causes. Aborted SCD occurred in 7 (10%) patients, 
syncope in 31 (46%), sustained ventricular tachycardia (VT) in 43 (63%), HF in 18 (26%), atrial 
fibrillation (AF) in 16 (24%) and 3 (4%) patients underwent heart transplant. Twenty-four (35%) 
patients had ICD implanted (15 and 5 of them received both appropriate and inappropriate 
interventions respectively and 7 experienced device-related complications). Of the ECG parameters 
registered at the enrolment, left anterior fascicular block (p=0.001), QRS duration in lead 1 
(p<0.001), Epsilon wave (p<0.001), T wave inversion in V4-V5-V6 (p=0.012, p=0.001 and 
p=0.006) and low QRS voltages (p=0.001) progressed over time. At multivariate analysis Epsilon 
wave (OR 20.9, CI 95% 1.8-239.8, p=0.015) was the only predictor of the composite endpoint of 
SCD, HF-related death or heart transplant.  
Conclusions:  Besides playing a pivotal role in ARVC diagnosis, a simple ECG features as Epsilon 
wave is a marker of poor prognosis. 
 
Abstract word count: 250 
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Abbreviation list: ARVC: Arrhythmogenic right ventricular cardiomyopathy; SCD: sudden cardiac 
death; TFC: Task Force Criteria; ECG: electrocardiographic; CMR: cardiac magnetic resonance; 
HF: heart failure; AF: atrial fibrillation; RVOT: right ventricle outflow tract. RV: right ventricle; 
VT: ventricular tachycardia; SD: standard deviation; ICD: implantable cardioverter defibrillator; 
ES: electrophysiologyic study; TIA: transient ischemic attack; CE: composite endpoint; VF: 
ventricular fibrillation. 
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Introduction 
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a rare inherited heart-muscle 
disease, characterized by adipose and fibrous tissue replacement of the cardiomyocytes, that 
primarily affects the right ventricle (RV). Due to identification of causative mutations in genes 
encoding desmosomal proteins the disease is a genetic myocardial dystrophy (1).  
ARVC leads to a wide spectrum of clinical manifestations, ranging from long-term favorable course 
to ventricular life-threatening arrhythmias, potentially causing sudden cardiac death (SCD) in 
young adults, and progressive right or biventricular heart failure (HF) (2). The Task Force Criteria 
(TFC) (3,4) base ARVC diagnosis on family history, specific electrocardiographic (ECG) features, 
ventricular arrhythmias, right ventricular functional and structural abnormalities, genetics and 
histopathological evidence of tissue replacement.  
Over the past years, new therapeutic options have been progressively introduced and clinical 
management  of patients with ARVC has shifted from the use of antiarrhythmic drugs (empirical 
and/or guided by the results of the electrophysiologic study (ES)) to the use of implantable cardiac 
defibrillators (ICD) and transcatheter ablation procedures. With this regard, to better guide 
clinicians in the management of ARVC patients, an international task force document (5) providing 
a standardized treatment flowchart has been recently published. 
Although several ECG, echocardiographic and cardiac magnetic resonance features of patients with 
ARVC have been described, their progression over time as well as the relation with long-term 
clinical outcomes has seldom been reported.  
Aims of the present study were to analyse the progression over time of relevant ECG findings in 
ARVC patients referred to a tertiary referral centre and to investigate their prognostic impact.   
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Methods 
Out of all patients followed to our tertiary referral center between 1970 and 2014 with cardiological 
clinical history onset with aborted SCD, syncope, palpitations, HF, ECG abnormalities or family 
screening, 68 patients (69% men, age 31±19 years) fulfilled the 1994 TFC for ARVC diagnosis 
(also post hoc validated with 2010 TFC). Twelve (18%) cases were clustered within five families. 
Following ARVC diagnosis, all patients underwent physical examination and 12-lead ECG 
recording during routine outpatient visits for a mean follow-up of 17±8 years.  
Patient’s management was based on the therapeutic flowchart reported in Figure 1. Patients were 
defined symptomatic if had experienced ventricular arrhythmia-related clinical manifestations such 
as syncope, palpitations and dyspnea. Avoidance of physical efforts, beta-blockade (primarily 
nadolol) and ES were recommended to all patients. Based on sustained ventricular tachycardia (VT) 
or ventricular fibrillation (VF) inducibility at baseline ES only beta-blocker therapy was continued 
or antiarrhythmic drugs (primarily sotalol or amiodarone) were started. During follow-up a second 
ES was proposed to evaluate antiarrhythmic drug efficacy and its results (e.g. persistent sustained 
VT/VF inducibility or clinical sustained VT despite maximal dose antiarrhythmic drug therapy) 
together with all known predictors of SCD (e.g. young age, aborted SCD or family history of SCD, 
ventricular tachycardia with hemodynamic compromise, unexplained syncope and RV or 
biventricular severe dysfunction) were taken into account for a global assessment of the most 
appropriate management and to decide about  ICD implantation. In selected cases, to reduce 
persistent symptoms, alternative antiarrhythmic drug associations were used and/or radiofrequency 
transcatheter ablation was performed. Patients presenting with aborted SCD at baseline were 
directly implanted with an ICD, associated with beta-blockade therapy and, if deemed necessary, 
antiarrhythmic drugs.  
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The following adverse clinical outcomes were recorded at the routine outpatient follow-up visits 
and/or by medical records: all-case death (including SCD), aborted SCD, syncope, sustained VT, 
HF, atrial fibrillation (AF), stroke/transient ischemic attack (TIA) and heart transplant. Aborted 
SCD was defined as a cardiac arrest requiring cardiopulmonary resuscitation or an appropriate ICD 
shock on VF. For the purpose of this study clinical events were combined in a composite endpoint 
(CE) of SCD, HF related death or heart transplant. 
Electrocardiographic parameters 
Based on previously published data, the following ECG parameters were assessed: presence of 
sinus rhythm; heart rate; P wave: (a) morphology in lead II and in lead V1 (positive, negative or 
biphasic), (b) voltage (mm) in lead II and in lead V1 and (c) duration (sec) in lead II and in lead V1; 
P-wave electrical axis (<0°, ≥0°and <90°, ≥90°); PQ interval duration (sec); QRS complex 
electrical axis (<0°, ≥0° and <105°, ≥105°) (6); mean QRS duration in lead V1 and V6 (sec); R/S 
ratio in lead V1 (6); QRS duration ≥110 msec in V1 and V2 leads; ratio of QRS duration in leads 
(V1+V2+V3)/(V4+V5+V6) (7); pathologic Q waves  (duration >40 msec and amplitude >1/4 of 
QRS complex) in frontal and precordial leads; R wave voltage (mm) in leads V1-V3; Epsilon wave 
(low amplitude potentials occurring immediately after the QRS complex in the right precordial 
leads); QRS dispersion >40 msec (difference in duration between the longest and the shortest QRS 
intervals in any lead) (8); left anterior fascicular block (rS pattern in the inferior leads and qR 
pattern in aVL with a front plane QRS axis of <-30° and QRS duration <120 msec) (6); complete or 
incomplete right bundle branch block (QRS duration >120 ms and QRS duration >110 msec and 
<120 msec respectively, with a secondary R wave in V1-V2 and wide deep S wave in V5-V6); 
prolonged S wave upstroke >55 msec (from S wave nadir up to isoelectric line) (9); T wave polarity 
in precordial leads (positive, negative, flat); QRS voltage in each limb lead ≤ 0.5 mvolt (10).  
Echocardiography 
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M-mode, two dimensional and Doppler echocardiography were used to evaluate cardiac chambers 
diameters and segmental or diffuse wall motion abnormalities. Apical four-chamber, parasternal, 
and subcostal echocardiographic projections were used to evaluate right ventricular outflow tract 
(RVOT) diameter, right ventricle (RV) dilatation, RV fractional area change (calculated by using 
the following formula: (end-diastolic area - end-systolic area)/end diastolic area measured in the 
apical 4-chamber view) and left ventricular ejection fraction (LVEF). All the measurements were 
defined according to ASE recommendations of 2005 (11), in particular RV dimension has been 
measured from an apical four chamber view in the mid-RV and defined mildly dilated when 34-37 
mm, moderately dilated when 38-41 mm and severely dilated when ≥ 42 mm.  
 
Cardiac Magnetic Resonance (CMR). 
CMR images were assessed for RV wall motion abnormalities (dyskinesia), RV volumes, RV and 
LV fibrofatty infiltration (intramyocardial high T1 signal) and LVEF. RV dilatation was defined 
moderate when RV telediastolic volume (TDV) was ≥100 ml/m² and <110 ml/m² (in male) or ≥90 
ml/m² and <100 ml/m² (in female) while it was defined severe when RVTDV was  ≥110 ml/m² (in 
male) or ≥100 ml/m² (in female). 
Statistical analysis 
Categorical variables are reported as count and percentages, while continuous variables as mean and 
standard deviation (SD). Changes over time of categorical and continuous ECG parameters were 
analyzed by McNemar lambda and paired T test respectively. Correlation between baseline ECG 
parameters and adverse clinical outcomes  as well as between baseline ECG and echocardiographic 
parameters was tested in cross tabulations tables by means of the Pearson Chi-Square or Fisher’s 
Exact Test and by one-way ANOVA respectively for categorical and continuous variables. Logistic 
regression was used to investigate the association between ECG parameters with the composite 
endpoint. All variables showing a p-value <0.1 at univariate analysis (amiodarone use, RV 
dyskinesia at baseline CMR considered as a marker of RV dysfunction, Epsilon wave at twelve lead 
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baseline ECG) were included in a multivariable model. Kaplan Meier curves were used to show 
composite endpoint occurrence stratified for the presence of Epsilon wave and log-rank test was 
used to test its association with the composite endpoint. A two sided p-value <0.05 was considered 
statistically significant; all analyses were performed with SPSS 16.0 (SPSS Inc, Chicago, IL, USA).  
 
Results 
Baseline features of the study population are listed in Table 1. Out of all patients 47 (69%) were 
men with a mean age of 31±19 years, 20 (29%) suffered hypertension, 3 (4.4%) previous stroke or 
TIA and 6 (8.8%) diabetes mellitus. Baseline echocardiography was performed in all study patients: 
the mean LVEF was almost normal (58±8%) while a moderate-severe RV dilatation was 
documented in 31 (46%) of them. Baseline CMR, was available in 57 patients:  RV dyskinesia  was 
observed in 16 patients (28%), RV moderate-severe dilatation in 33 (57%) and fibrofatty RV 
involvement in 37 patients (64%). 
Referral of the 68 ARVC patients was triggered by a chief complaint of palpitations in 43 cases 
(63%), 15 (22%) of whom with documented sustained VT; syncope in 8 (12%); ECG abnormalities 
in 5 (7%);  family screening in 9 (13%), 7 (10%) of whom with family history of SCD; aborted 
SCD and HF in 1 and 2 (1.5% and 3%) cases respectively. Overall, 54 patients (79%) presented 
with symptoms, 39 (72%) during effort. Family history of ARVC was present in 18 patients (26%) 
while 22 (32%) had family history of SCD.   
Clinical management 
Besides avoidance of physical efforts, all patients were started on a beta-blocker at enrolment. 
Baseline ES was performed in 61 patients (89%) and resulted positive for sustained VT/VF 
inducibility in two third 39 (64%). A follow-up ES, in order to test beta blocker and antiarrhythmic 
therapy efficacy, was performed in 33 patients (49%) and resulted still positive in 21 (63%). One 
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patient was enrolled following an aborted SCD and directly underwent ICD implantation in addition 
to the administration of nadolol and amiodarone. Overall 24 patients (35%) underwent an ICD 
implantation and 17 (25%) underwent sustained VT transcatheter ablation.  
During a mean follow-up of 17±8 years 12 (18%) patients died: 3 for SCD, 4 for end-stage HF and 
5 for non-cardiac causes (3 cancers, 1 car accident, 1 end-stage renal failure). Details regarding the 
3 SCD events are as follows: 1) one SCD episode occurred in a 18 years old patient  with positive 
ES despite sotalol; he had ICD implantation postponed due to patient’s preferences (i.e. because of 
a concomitant school exam); 2) another SCD was observed in a 60 years old woman followed for 
21 years that 6 months before autonomously decided to stop nadolol and amiodarone therapy; 3) the 
third SCD episode occurred in a 46 years old woman that following appropriate ICD shock for VF 
experienced a new VF episode one week later which was not recognized and left untreated by the 
device due to a concomitant lead fracture. Seven cardiovascular deaths occurred during follow-up, 
accounting for an annual cardiovascular mortality rate of 0.58% person/year (0.25% person/year for 
SCD and 0.33% person/year for end-stage HF). Aborted SCD occurred in 7 patients (0.58% 
person/year): 1 during hospitalization (before sustained VT catheter ablation) and 6 in ICD carriers. 
Syncope was reported in 31 patients (2.58% person/year), sustained VT in 43 patients (3.59% 
person/year), HF in 18 (1.50% person/year), AF in 16 (1.33% person/year), stroke/TIA in 9 (0.75% 
person/year) and heart transplant in 3 patients (0.25% person/year).  
Overall SCD, HF-related death and heart transplant occurred in 10 patients (15%). Within the 24 
(35%) ICD patients, 15 (63%) received an appropriate intervention (triggered by VF in 6 patients 
and by sustained VT in 9), 5 (21%) received an inappropriate intervention and 7 (29%) had device-
related complications (1 pocket hematoma, 1 infection, 3 lead dislocations and 2 lead fracture). Five 
patients died for cardiac causes despite ICD implantation (1 for SCD secondary to lead fracture, 4 
for HF) and three patients underwent heart transplantation. VT/VF induction at baseline ES did not 
relate with appropriate ICD interventions during follow-up (p= 0.211). 
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Electrocardiographic progression and correlation with prognosis 
ECG parameters are detailed in Table 2. Mean time between enrolment and follow-up ECG was 
10±7 (range 3-23) years. Of the ECG parameters registered at the enrolment, left anterior fascicular 
block (p=0.001), QRS duration in lead 1 (p<0.001), Epsilon wave (p<0.001), T wave inversion in 
leads V4-V5-V6 (p=0.012, p=0.001 and p=0.006 respectively) and low QRS voltages (p=0.001) 
showed progression  over time. Table 3 presents the univariate analysis investigating the association 
between ECG parameters and the composite endpoint of SCD, HF-related death or heart transplant: 
Epsilon wave was the only ECG predictor of the adverse outcome (60% vs 24%, p= 0.016). In 
addition, the multivariable analysis confirmed Epsilon wave as an independent predictor of the 
composite endpoint (OR 20.9, CI 95% 1.8-239.8, p=0.015).  
In analyzing the relationship between ECG and echocardiographic progression over time we found 
a significant association between RVOT dilatation and QRS duration ≥110 msec in V1 and V2 
leads (p=0.037). Also, the development of moderate-severe RV dilatation showed a borderline 
association with the development of QRS dispersion >40 msec (p=0.060).  
Kaplan-Meier plots show that Epsilon wave was significantly associated with the occurrence of  CE 
during  long term follow-up (Log Rank p value = 0.019, Figure 2). 
Discussion 
This single centre observational study describes long-term clinical outcome and ECG features of 68 
ARVC patients referred to a tertiary referral centre for clinical management.  
The prevalence of adverse events widely varies in ARVC long term follow-up studies, depending 
on characteristics of patients enrolled and therapeutic approaches used, with SCD and HF 
occurrence ranging from 2% (12) to 13% (2,13) and from 3% (2) to 10% (14) respectively.  
As described in the results, in our study 3 SCD occurred in specific clinical settings as a 
consequence of drug therapy withdrawal, postponed ICD implantation and ICD malfunctioning (i.e 
VF undersensing due to lead fracture). The low percentage of SCD (4.4%) is surely influenced by 
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the high number of patients with an ICD (35%); what should be underlined is that patients with an 
ICD seem to experience a higher cardiovascular mortality, mainly driven by HF-related death, 
compared with those without an ICD (20% vs 4%). This may be due to the fact that ICD 
implantation was performed amongst patients with more advanced disease stage. Although ICD 
implantation is the most effective therapy for SCD prevention, inappropriate interventions and 
device-related complications represent important issues, especially considering the generally young 
age of patients with ARVC. In our cohort 24 patients received an ICD and were followed for a 
mean of 10 years (9.7±4.4 years). Mortality rate was high (20%), mainly secondary to HF 
progression, but in one patient, SCD occurred despite ICD because of lead fracture and subsequent 
failure in recognizing and treating a VF episode. Inappropriate interventions (21%) and device-
related complications (29%) were comparable to previous published studies. In fact, previous mid-
term follow-up studies (15-16) on ICD implantation in ARVC patients  reported mortality rates of 
about 2-3%, inappropriate interventions ranging from 16% to 24% and device-related complications 
in about 14% of the patients. Conversely in a long term follow-up study (17) (80±43 months of 
follow-up) mortality rates were higher (13%) as well as incidence of device-related complications 
(42%). Considering all these data physicians managing ARVC patients should always keep in mind 
the risk of long-term complications associated with an ICD and the fact that this therapeutic 
approach does not modify the anatomic substrate nor slow the progression of the disease.  
Until now, the role of ES in ARVC patients has been  controversial (15,18,19,20). In particular, in 
our study the limited number of patients undergoing ICD implantation following electrophysioligc 
study may explain the lack of significant relationship between a positive result to ES and 
appropriate ICD intervention during follow-up observed in the study population. However, the use 
of ES to evaluate the efficacy of antiarrhythmic treatment and for risk stratification, together with 
appropriate indications to ICD implantation, have, in our opinion, contributed to the overall low 
incidence of arrhythmic deaths observed during long term follow-up. 
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Although several studies have analysed ECG features of patients with ARVC, their progression 
over time and their prognostic impact remain controversial (6,21). Several ECG abnormalities have 
shown to develop over time reflecting disease progression and involvement of new myocardial 
areas as Epsilon wave, QRS enlargement in lead 1 and T wave inversion in the precordial leads 
(13,22,23,24). Epsilon wave, a marker of RV delayed activation due to late electrical depolarization 
of isolated myocytes in the context of fibro-fatty tissue substitution, should directly be correlated 
with progressive RV involvement and therefore with a poor outcome. In the present study Epsilon 
wave was associated with the occurrence of SCD, HF-related death and heart transplant. Previous 
experiences, instead, somewhat failed to report this correlation: Shulin Wu et al (25) reported the 
presence of Epsilon wave in 80% of patients at high-risk of cardiovascular mortality (previous 
sustained VT and RV failure) and in 51% of low-risk patients, not reaching statistical significance 
(p=0.16) and Turrini et al (26) reported no difference in Epsilon wave incidence in ARVC patients 
with different risk (35% in patients who died suddenly, 25% in patients with sustained VT and 30% 
in asymptomatic patients). Syncope and HF could be considered as clinical manifestations of fast 
and sustained VT leading to hemodynamic compromise. In addition, in patients with ARVC, it has 
been previously shown that RV dysfunction is often paralleled by regional LV dysfunction, 
potentially contributing to clinical deterioration (27). 
Several limitations should be acknowledged interpreting study results. First, the present study 
enrolled patients referred to a tertiary referral centre for symptoms, ECG abnormalities or family 
history of ARVC: considering that SCD may be the first clinical manifestation in a sub-group of 
high risk ARVC patients, the clinical cohort hereby considered may not be representative of the 
general ARVC population. Second, due to the observational design of the study, inherent biases 
cannot be excluded as not-simultaneous execution of baseline instrumental examinations (ECG, 
echocardiography and CMR). Third, considering the limited sample size and the low number of 
adverse clinical events the statistical power of the multivariate logistic regression model is limited. 
Fourth, data regarding RV ejection fraction at baseline CMR was available for a minority of 
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patients. Finally, since ECG changes in ARVC are dynamic, the evaluation of two ECGs only may 
have not discriminated between true ECG progression and dynamic fluctuations. 
Conclusion 
The occurrence of adverse events such as sustained VT, HF, AF and stroke is common among 
patients with ARVC. ICD implantation is indeed effective in preventing SCD but the high incidence 
of HF-related death in this cohort of patients highlights the inability of the ICD to modify the 
prognosis related to the progression of the substrate of the disease. Besides playing a pivotal role in 
ARVC diagnosis, a simple ECG features like Epsilon wave is a marker of poor prognosis. 
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Figure legend. 
Figure 1. Therapeutic flowchart relevant to the clinical management of the study population. 
aSCD=aborted sudden cardiac death; BB=beta-blockade; AAD=antiarrhythmic drugs; 
ICD=implantable cardiac defibrillator; ES=electrophysiological study; SCD=sudden cardiac 
death.  
*Predictors of SCD: younger age, family history of SCD, ventricular tachycardia with 
hemodynamic compromise, unexplained syncope and RV or biventricular severe dysfunction 
 
Figure 2. Event Free Survival from composite endpoint (CE) stratified for the presence of Epsilon 
wave. Patients with Epsilon wave have higher risk of CE occurrnce during long-term follow-up 
(Log Rank p value = 0.019). 
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